Full-Time
Regional Head of Sales
Posted on 1/13/2026
Biomodal
51-200 employees
Hardware-agnostic multiomics sequencing for research
No salary listed
United Kingdom
In Person
Extensive travel across the EMEA region required.
 Sales & Account Management (2) |
|---|
| , |
- Demonstrated success leading sales teams or managing salespersons with a proven track record of hitting targets and delivering results
- Deep understanding of genomics technologies, target markets and customer segments including: academic labs, CROs, pharma, biotech and translational labs
- Exceptional communication skills in English – written and oral; must be a very strong public speaker; additional European languages are a strong advantage
- Exceptional organizational skills – planning and follow through, accurate forecasting and pipeline management, strategic planning
- Strong leadership – track record of building and retaining high performance sales teams
- Self-starter, solution oriented, collaborative, team-player; a “can-do” and “customer first” mentality
- Willingness to travel extensively across region
- Bachelor degree required
- Develop and execute a regional sales strategy aligned with global business objectives
- Lead, mentor, and manage a high-performing sales team, including hiring, training, and performance management
- Set clear KPIs and sales targets for the team and ensure consistent achievement through coaching and accountability
- Identify and cultivate strategic opportunities across academic, clinical, and biopharma sectors
- Build and maintain executive-level relationships with key customers and partners
- Oversee accurate forecasting, pipeline management, and CRM reporting across the region
- PhD and/or MBA preferred
- Additional European languages are a strong advantage
Biomodal develops multiomics tools that analyze both genetic and epigenetic data from a single, small DNA sample using the duet multiomics platform. It reads the standard four DNA bases plus two modified bases (5mC and 5hmC) to produce a 6-base genome, with results fed through a software pipeline and compatible with existing sequencing machines. The approach is hardware-agnostic and provides a single workflow that covers genetics and epigenetics, unlike tools that focus on one aspect or require special instruments. Its goal is to equip life scientists and clinical developers with practical tools to accelerate biomarker discovery and research into cancer, neurodegenerative diseases, aging, and liquid biopsy applications.
Company Size
51-200
Company Stage
Series D
Total Funding
$185.1M
Headquarters
Cambridge, United Kingdom
Founded
2012
Simplify's Take
What believers are saying
- duet evoC compatibility with Element AVITI boosts sensitivity in cancer and aging research.
- Dennis Yuk Ming Lo joins scientific advisory board enhancing liquid biopsy expertise.
- 95% bases above Q30 accuracy powers precise disease classifiers from limited samples.
What critics are saying
- Illumina integrates native epigenetics into NovaSeq collapsing Biomodal's value in 12 months.
- 10x Genomics Xenium expands spatial multiomics cannibalizing Biomodal's market in 6 months.
- No Series E since 2021 depletes cash forcing dilutive financing in 12 months.
What makes Biomodal unique
- Biomodal's duet evoC sequences 6-base genome distinguishing 5mC and 5hmC at single-base resolution.
- Platform-agnostic duet integrates with existing sequencers for single-sample genetic-epigenetic analysis.
- +modC enables low-volume cfDNA multiomics for cancer and neurodegenerative biomarker discovery.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
Paid Vacation
Performance Bonus
401(k) Retirement Plan
Home Office Stipend
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 1%2 year growth
↑ 3%Biomodal, an omics-based life sciences technology company, has announced that its duet multiomic solutions are now compatible with Element Biosciences' AVITI24 5D multiomics and AVITI sequencing instruments. The integration, validated at the University of Minnesota Genomics Center, aims to enhance sensitivity for cancer, ageing and neurodegenerative disease research. The collaboration combines biomodal's 5-base and 6-base sequencing solutions with Element's sequencing systems, enabling complete methylation detection and delivering actionable insights within a single streamlined process. AVITI users gain access to biomodal's software pipeline, creating an end-to-end workflow for next-generation sequencing. Biomodal's platform-agnostic technology integrates pre-sequencing workflow with post-sequencing informatics to generate genetic and epigenetic data from a single sample in one run.
CAMBRIDGE, England--(BUSINESS WIRE)--biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC). The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, G, C, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC), on the same DNA molecule. This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA). The advanced 6-base genome data enables the exploration of epigenetic mechanisms of gene regulation through methylation and hydroxymethylation. Researchers now are able to obtain an accurate measurement of 5mC and 5hmC, integrated into local genetic context, with 95% of bases above Q30 and 50% with accuracy above Q40. By measuring multiple modes of biology from a single low-input DNA sample in a single experiment, researchers can use the comprehensive data to build predictive models of gene expression, chromatin accessibility, and enhancer status to better understand the biological mechanisms that link genotype to phenotype
Biomodal, formerly Cambridge Epigenetix, has appointed Dennis Yuk Ming Lo to its scientific advisory board and Omead Ostadan to its board of directors.
Cambridge Epigenetix (CEGX), a life sciences tools and technology company which is revolutionizing genome sequencing, has announced the appointment of Peter J. Fromen as Chief Executive Officer effective July 18, 2022.
Cambridge Epigenetix (CEGX), a life sciences tools and technology company revolutionising...